Do pts w autoimmune disease (AID) respond differently to immune checkpoint inhibitors (ICI) & have different mortality or iRAE risk vs pts without AID? Study of pts on ICI showed no significant difference in mortality in pts w & without pre-existing AID Ab2532 #ACR24 @RheumNow https://t.co/suywDdGIB1

• https://x.com/DrMiniDey/status/1858534127064019181/photo/1

Applying the guidelines to Cases- Dr M Dall’Era for a pt wit extrarenal lupus and active LN. #ACR24 @rheumnow https://t.co/lvOUWjEdEz

• https://x.com/KDAO2011/status/1858534463073861691/photo/1
• https://x.com/KDAO2011/status/1858534463073861691/photo/1
• https://x.com/KDAO2011/status/1858534463073861691/photo/1
• https://x.com/KDAO2011/status/1858534463073861691/photo/1

Non-pharm tx in TAK - not something we always think about but… Impressive effect of resistance exercise!! Not just in symptoms but also inflammatory markers Per Dr. Springer - even a stress ball could be enough for UE vascular health in these pt @RheumNow #ACR24 https://t.co/3O46gobbMX

• https://x.com/Dr_Brian_MD/status/1858534823310069933/photo/1
• https://x.com/Dr_Brian_MD/status/1858534823310069933/photo/1

The updated 2024 ACR Guideline for Dx and Tx of #lupus nephritis is here! Dr. Lisa Samaritano discusses the key recommendations 👇 For all pts: screen for LN, give HCQ and RAAS for pts with ⬆️ proteinuria GCs in pts w/ LN class III/IV &/or V. @Rheumnow #ACR24 @rheumarhyme https://t.co/wLVRGktR59

• https://x.com/RHEUMarampa/status/1858534848090021939/photo/1
• https://x.com/RHEUMarampa/status/1858534848090021939/photo/1

The overview for #lupus nephritis tx. Triple therapy is preferred as first line due to: 1. RCTs (BLISS-LN & AURORA 1) showing improved outcomes w/ triple txs 2. Nephron loss happens with ongoing LN - time is kidney! @RheumNow #ACR24 https://t.co/IQo3q3O1pt

• https://x.com/RHEUMarampa/status/1858534869514523055/photo/1
• https://x.com/RHEUMarampa/status/1858534869514523055/photo/1

Overall very reasonable, aligning ACR recs w/other guidance groups & updated data Remember: guidelines are meant to be broken. Some patients can likely avoid pulse, others may need more steroid on the back end, biopsies are not benign #ACR24 @RheumNow

Recommend "Triple Therapy" = Glucocorticoids + two other agents Practically, that means MMF + belimumumab OR CNI for most pts For the CYC afficionados, the lower-dose EUROLUPUS protocol is preferred #ACR24 @RheumNow https://t.co/0gRISXSw0c

• https://x.com/EBRheum/status/1858535181373563219/photo/1

Happening now, new guidelines for mgmt. A few highlights: Recommend prompt GC therapy, pulse x1-3d followed by oral pred (<0.5mg/kg/d) w/taper to <5mg by 6 months Aligns with EULAR recs for a much-lower dose than most clinicians currently doing #ACR24 @RheumNow https://t.co/B71i7FBYlQ

• https://x.com/EBRheum/status/1858535178517303725/photo/1

Applying the #ACR24 #LupusNephritis: Case 2 by Dr M Dall’Era @RheumNow https://t.co/A7i103uHZT

• https://x.com/KDAO2011/status/1858535623595835495/photo/1
• https://x.com/KDAO2011/status/1858535623595835495/photo/1
• https://x.com/KDAO2011/status/1858535623595835495/photo/1
• https://x.com/KDAO2011/status/1858535623595835495/photo/1

Interesting! Study of pts w/ ANA(-) & dsDNA(+). 1 in 5 dx with APLS! Have others seen that? I have been disgregarding this pattern, though some of that is related to my in-house assay (seems overly-sensitive) & my bias against overdiagnosis #ACR24 @RheumNow Abstr#2391 https://t.co/FWgCjEwPDK

• https://x.com/EBRheum/status/1858536139990188151/photo/1

Abstract 2503: Clofutriben (HSD-1 inhibitor) minimizes adrenal suppression. Adding clofutriben to prednisolone boosts ACTH & cortisol levels with fewer patients with suppressed morning cortisol (≤5.0 mg/dL) (34% vs 14%). @RheumNow #ACR24 #GCTox

Biosimilar switching in practice Hyrich: UK experience Switching to biosimilar has no immediate benefit to patients but saves NHS money Allows for gain share that can be re-invested in pt care Transparency in switching in explaining to pts and offering resource @RheumNow #ACR24

Abstract 1876: Developed a machine learning model w/ #SDoH covariates to accurately identify patients with SLE and ESRD in NIH All of US dataset @RheumNow #ACR24 https://t.co/TLDSiBZZPs

• https://x.com/AkhilSoodMD/status/1858536391875113060/photo/1

Low uveitis rates in patients with axial spondyloarthritis and psoriatic arthritis treated with bimekizumab (BKZ) over the long term. Key findings: - AxSpA: 3.7% incidence (1.3/100 PY) with BKZ. - PsA: Only 0.2% incidence (0.1/100 PY). - All events were mild/moderate, with no… https://t.co/jkUwHJk3FJ https://t.co/gTcCzeC88e

• https://x.com/i/web/status/1858536895019438208
• https://x.com/synovialjoints/status/1858536895019438208/photo/1

If you’re starting with DMARD (according to ACR/VF guidelines) tx in TAK - MTX and AZA are probably equivalent options… MMF not so much @RheumNow #ACR24 https://t.co/jn52ujtspo

• https://x.com/Dr_Brian_MD/status/1858537546902335997/photo/1